In the per protocol analysis at 1 year , bevacizumab was equivalent to ranibizumab , with 7.9 and 8.2 mean letters gained , respectively ( 95 % confidence interval [ CI ] of mean difference , -2.4 to 2.9 ; P = 0.845 ) .